Clinical Policy: Methoxy Polyethylene Glycol-epoetin Beta (Mircera)
Reference Number: ERX.SPA.323
Effective Date: 02.19.19
Last Review Date: 05.19

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Methoxy polyethylene glycol-epoetin beta (Mircera®) is an erythropoiesis-stimulating agent (ESA).

FDA Approved Indication(s)
Mircera is indicated for the treatment of anemia associated with chronic kidney disease (CKD) in:
• Adult patients on dialysis and patients not on dialysis
• Pediatric patients 5 to 17 years of age on hemodialysis who are converting from another ESA after their hemoglobin level was stabilized with an ESA.

Limitation(s) of use:
• Mircera is not indicated and is not recommended for use:
  o In the treatment of anemia due to cancer chemotherapy
  o As a substitute for red blood cell transfusions in patients who require immediate correction of anemia.
• Mircera has not been shown to improve symptoms, physical functioning or health-related quality of life.

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

Health plan approved formularies should be reviewed for all coverage determinations. Requirements to use preferred alternative agents apply only when such requirements align with the health plan approved formulary.

It is the policy of health plans affiliated with Envolve Pharmacy Solutions™ that Mircera is medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Anemia Due to Chronic Kidney Disease (must meet all):
      1. Diagnosis of anemia of CKD, and member meets one of the following (a or b):
         a. Age ≥ 18 years (dialysis status is irrelevant);
         b. Age 5 to ≤ 17 years, on dialysis, and will be converting from another ESA agent (e.g., epoetin alfa, darbepoetin alfa);
      2. Prescribed by or in consultation with a hematologist or nephrologist;
      3. Adequate iron stores as indicated by current (within the last 3 months) serum ferritin level ≥ 100 mcg/L or serum transferrin saturation ≥ 20%;
      4. Pretreatment hemoglobin < 10 g/dL;
      5. Failure of Procrit® and Aranesp®, unless contraindicated or clinically significant adverse effects are experienced;
         *Prior authorization is required for Procrit and Aranesp
      6. Dosing interval does not exceed one of the following (a or b):
         a. Adults: SC or IV once every two weeks;
         b. Pediatrics: IV once every four weeks.
   Approval duration: 6 months
B. Other diagnoses/indications
   1. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III
      (Diagnoses/Indications for which coverage is NOT authorized).

II. Continued Therapy
   A. Anemia Due to Chronic Kidney Disease (must meet all):
      1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions or
         member has previously met initial approval criteria;
      2. Member is responding positively to therapy;
      3. Adequate iron stores as indicated by current (within the last 3 months) serum ferritin level ≥
         100 mcg/L or serum transferrin saturation ≥ 20%;
      4. Dosing interval does not exceed one of the following (a or b):
         a. Adults: SC or IV once every two weeks;
         b. Pediatrics: IV once every four weeks.
      Approval duration: 6 months

   B. Other diagnoses/indications (must meet 1 or 2):
      1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions
         and documentation supports positive response to therapy,
         Approval duration: Duration of request or 6 months (whichever is less); or
      2. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III
         (Diagnoses/Indications for which coverage is NOT authorized).

III. Diagnoses/Indications for which coverage is NOT authorized:
   A. Anemia due to cancer chemotherapy;
   B. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient
      documentation of efficacy and safety according to the off-label use policy – ERX.PA.01 or
      evidence of coverage documents.

IV. Appendices/General Information
   Appendix A: Abbreviation/Acronym Key
   CKD: chronic kidney disease
   ESA: erythropoiesis-stimulating agent
   FDA: Food and Drug Administration
   RBC: red blood cell

   Appendix B: Therapeutic Alternatives
   This table provides a listing of preferred alternative therapy recommended in the approval criteria.
   The drugs listed here may not be a formulary agent and may require prior authorization.

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Regimen</th>
<th>Dose Limit/Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Procrit (epoetin alfa)</td>
<td>Anemia due to CKD</td>
<td>Varies</td>
</tr>
<tr>
<td>Adults:</td>
<td>50-100 Units/kg IV or SC TIW</td>
<td></td>
</tr>
<tr>
<td>Pediatrics (age 1 month or older):</td>
<td>50 Units/kg IV or SC TIW</td>
<td></td>
</tr>
<tr>
<td>Aranesp (darbepoetin alfa)</td>
<td>Anemia due to CKD</td>
<td>Varies</td>
</tr>
<tr>
<td>CKD on dialysis: starting dose 0.45 mcg/kg IV or SC weekly, or 0.75 mcg/kg IV or SC every 2 weeks. IV recommended for patients on hemodialysis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CKD not on dialysis: starting dose 0.45 mcg/kg IV or SC at 4 week intervals</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Drug Name | Dosing Regimen | Dose Limit/Maximum Dose
--- | --- | ---
Pediatric patients with CKD: starting dose 0.45 mcg/kg IV or SC weekly; patients with CKD not on dialysis may also be initiated at 0.75 mcg/kg every 2 weeks

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings
- Contraindication(s):
  - Uncontrolled hypertension
  - Pure red cell aplasia (PRCA) that begins after treatment with erythropoietin protein drugs
  - Allergic reactions, anaphylaxis
- Boxed warning(s): ESAs increase the risk of death, myocardial infarction, stroke, venous thromboembolism, thrombosis of vascular access and tumor progression or recurrence

V. Dosage and Administration

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anemia due to CKD</td>
<td><strong>Adult patients with CKD on or not on dialysis</strong>&lt;br&gt;Initial treatment: 0.6 mcg/kg body weight SC or IV once every two weeks&lt;br&gt;Maintenance treatment: dose twice that of the every-two-week dose SC or IV once monthly&lt;br&gt;Conversion from another ESA: dosed SC or IV once monthly or once every two weeks based on total weekly epoetin alfa or darbepoetin alfa dose at time of conversion&lt;br&gt;&lt;strong&gt;Pediatric patients with CKD on hemodialysis**&lt;br&gt;Conversion from another ESA: dosed IV once every four weeks based on total weekly epoetin alfa or darbepoetin alfa dose at time of conversion.</td>
<td>Varies</td>
</tr>
</tbody>
</table>

VI. Product Availability
Injection (single-dose prefilled syringe): 30, 50, 75, 100, 120, 150, 200, or 250 mcg in 0.3 mL solution; 360 mcg in 0.6 mL solution

VII. References

Reviews, Revisions, and Approvals

<table>
<thead>
<tr>
<th>Policy created</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>02.19.19</td>
<td>05.19</td>
<td></td>
</tr>
</tbody>
</table>

Important Reminder
This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of
physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information.

This Clinical Policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members.

This policy is the property of Envolve Pharmacy Solutions. Unauthorized copying, use, and distribution of this Policy or any information contained herein is strictly prohibited. By accessing this policy, you agree to be bound by the foregoing terms and conditions, in addition to the Site Use Agreement for Health Plans associated with Envolve Pharmacy Solutions.

©2019 Envolve Pharmacy Solutions. All rights reserved. All materials are exclusively owned by Envolve Pharmacy Solutions and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Envolve Pharmacy Solutions. You may not alter or remove any trademark, copyright or other notice contained herein.